oxonic acid has been researched along with Vomiting in 19 studies
Oxonic Acid: Antagonist of urate oxidase.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration." | 9.30 | Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. ( Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S, 2019) |
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 9.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "Palonosetron was not superior to granisetron in combination antiemetic therapy." | 5.43 | Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. ( Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K, 2016) |
| "Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration." | 5.30 | Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. ( Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S, 2019) |
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 5.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "Previous studies have shown sex-related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown." | 2.90 | Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. ( Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Koizumi, W; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2019) |
| "The purpose of this phase I study of the dose escalation of oxaliplatin in combination with oral S-1 and pelvic radiation preoperatively for poor-risk lower rectal cancer was to determine the dose-limiting toxicity (DLT) and recommended dose of oxaliplatin." | 2.80 | A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. ( Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015) |
| " Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity." | 2.76 | [Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer]. ( Jin, ZM; Zhu, QC, 2011) |
| " Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle." | 2.75 | Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ( Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C, 2010) |
| "Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC." | 1.46 | Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017) |
| "Palonosetron was not superior to granisetron in combination antiemetic therapy." | 1.43 | Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. ( Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K, 2016) |
| " With regard to adverse events, the rates of nausea (p<0." | 1.42 | [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer]. ( Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H, 2015) |
| " Severe adverse events were observed in 22 patients (91." | 1.42 | Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck. ( Honda, K; Ishikawa, K; Sato, T; Suzuki, S; Yamazaki, K, 2015) |
| "In 62 gastric cancer patients treated with S-1 alone, data relating to the occurrence of gastrointestinal toxicity (diarrhea, vomiting, and nausea) and possible contributing factors were retrospectively collected, and logistic regression analysis was performed." | 1.40 | Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer. ( Chisaki, Y; Hira, D; Morita, SY; Noda, S; Terada, T; Yano, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (89.47) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Kobayashi, S | 1 |
| Ueno, M | 2 |
| Ogawa, G | 1 |
| Fukutomi, A | 2 |
| Ikeda, M | 3 |
| Okusaka, T | 4 |
| Sato, T | 2 |
| Ito, Y | 2 |
| Kadota, T | 1 |
| Ioka, T | 2 |
| Sugimori, K | 2 |
| Sata, N | 1 |
| Nakamori, S | 2 |
| Shimizu, K | 3 |
| Mizuno, N | 2 |
| Ishii, H | 3 |
| Furuse, J | 4 |
| Morizane, C | 2 |
| Mizusawa, J | 1 |
| Katayama, H | 1 |
| Ozaka, M | 1 |
| Okano, N | 2 |
| Hara, H | 1 |
| Yanagimoto, H | 1 |
| Wada, K | 1 |
| Tobimatsu, K | 1 |
| Yane, K | 1 |
| Yamaguchi, H | 2 |
| Asagi, A | 1 |
| Yukisawa, S | 1 |
| Kojima, Y | 1 |
| Kawabe, K | 1 |
| Kawamoto, Y | 1 |
| Sugimoto, R | 1 |
| Iwai, T | 1 |
| Nakamura, K | 1 |
| Miyakawa, H | 1 |
| Yamashita, T | 1 |
| Hosokawa, A | 1 |
| Kato, N | 1 |
| Shioji, K | 1 |
| Nakagohri, T | 1 |
| Kamata, K | 1 |
| Fang, M | 1 |
| Song, T | 1 |
| Liang, X | 1 |
| Lv, S | 1 |
| Li, J | 1 |
| Xu, H | 1 |
| Luo, L | 1 |
| Jia, Y | 1 |
| Hamada, C | 1 |
| Ikari, T | 1 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Imai, S | 1 |
| Okamura, S | 1 |
| Wang, F | 1 |
| Fan, QX | 1 |
| Wang, HH | 1 |
| Han, DM | 1 |
| Song, NS | 1 |
| Lu, H | 1 |
| Yamada, Y | 1 |
| Koizumi, W | 1 |
| Nishikawa, K | 1 |
| Gotoh, M | 1 |
| Fuse, N | 1 |
| Sugimoto, N | 1 |
| Nishina, T | 1 |
| Amagai, K | 1 |
| Chin, K | 1 |
| Niwa, Y | 1 |
| Tsuji, A | 1 |
| Imamura, H | 1 |
| Tsuda, M | 1 |
| Yasui, H | 2 |
| Fujii, H | 1 |
| Yamaguchi, K | 1 |
| Hironaka, S | 1 |
| Shimada, K | 1 |
| Hyodo, I | 1 |
| Ohue, M | 1 |
| Hamaguchi, T | 1 |
| Sakai, D | 1 |
| Noura, S | 1 |
| Kinugasa, Y | 1 |
| Fujita, S | 1 |
| Shimada, Y | 1 |
| Saito, N | 1 |
| Moriya, Y | 1 |
| Tang, Y | 1 |
| Wang, W | 1 |
| Teng, XZ | 1 |
| Shi, L | 1 |
| Chisaki, Y | 1 |
| Noda, S | 1 |
| Hira, D | 1 |
| Morita, SY | 1 |
| Yano, Y | 1 |
| Terada, T | 1 |
| Tanaka, H | 1 |
| Mitsunaga, S | 1 |
| Kobayashi, M | 1 |
| Funazaki, H | 1 |
| Katayama, S | 1 |
| Kuwahara, A | 1 |
| Okuyama, H | 1 |
| Takahashi, H | 1 |
| Ohno, I | 1 |
| Shimizu, S | 1 |
| Sakamoto, Y | 1 |
| Kondo, S | 1 |
| Ueno, H | 1 |
| Ochiai, A | 1 |
| Suzuki, S | 1 |
| Honda, K | 1 |
| Yamazaki, K | 1 |
| Ishikawa, K | 1 |
| Oyama, K | 2 |
| Fushida, S | 2 |
| Kaji, M | 2 |
| Takeda, T | 2 |
| Yabushita, K | 2 |
| Nezuka, H | 1 |
| Kinami, S | 2 |
| Kadoya, N | 1 |
| Takai, Y | 2 |
| Tsukioka, Y | 1 |
| Ohyama, S | 1 |
| Tsuji, K | 1 |
| Tsukada, T | 2 |
| Kinoshita, J | 2 |
| Fujimura, T | 2 |
| Ohta, T | 2 |
| Kasai, T | 1 |
| Nakamura, Y | 1 |
| Fukuda, M | 1 |
| Kitazaki, T | 1 |
| Nagashima, S | 1 |
| Takatani, H | 1 |
| Nakano, H | 1 |
| Nakatomi, K | 1 |
| Ikeda, T | 1 |
| Tsukamoto, K | 1 |
| Oka, M | 1 |
| Kohno, S | 1 |
| Arima, S | 1 |
| Okamoto, T | 1 |
| Toki, M | 1 |
| Suzuki, Y | 1 |
| Naruge, D | 1 |
| Kawai, K | 1 |
| Kobayashi, T | 1 |
| Kasuga, A | 1 |
| Kitamura, H | 1 |
| Takasu, A | 1 |
| Nagashima, F | 1 |
| Sugiyama, M | 1 |
| Park, I | 1 |
| Lee, JL | 2 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Kim, TW | 2 |
| Sym, SJ | 1 |
| Lee, SS | 1 |
| Jang, G | 1 |
| Yoo, C | 1 |
| Bae, KS | 1 |
| Kang, YK | 1 |
| Hong, YS | 1 |
| Park, JH | 1 |
| Kim, JH | 1 |
| Yoon, SN | 1 |
| Lim, SB | 1 |
| Yu, CS | 1 |
| Kim, MJ | 1 |
| Jang, SJ | 1 |
| Lee, JS | 1 |
| Kim, JC | 1 |
| Zhu, QC | 1 |
| Jin, ZM | 1 |
| Hirono, Y | 1 |
| Yoshimoto, K | 1 |
| Hirosawa, H | 1 |
| Nakano, T | 1 |
| Kimura, H | 1 |
| Yasui, T | 1 |
| Tsuneda, A | 1 |
| Shirasaka, T | 1 |
| Shimamoto, Y | 1 |
| Kato, T | 1 |
| Fukushima, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Carrilizumab Combinated With Gemcitabine and Oxaliplatin (GEMOX) as a Preoperative Translational Therapy for Unresectable Gallbladder Cancer[NCT05919095] | Phase 2 | 37 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for oxonic acid and Vomiting
| Article | Year |
|---|---|
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor | 1998 |
11 trials available for oxonic acid and Vomiting
| Article | Year |
|---|---|
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deo | 2019 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; | 2017 |
Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Respons | 2019 |
A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; A | 2015 |
Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non- | 2014 |
A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dr | 2016 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co | 2017 |
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relat | 2010 |
Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2011 |
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Colo | 2011 |
7 other studies available for oxonic acid and Vomiting
| Article | Year |
|---|---|
Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials as Topic; Drug C | 2021 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2017 |
Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer.
Topics: Aged; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastric Mucosa; Histami | 2014 |
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gastrointest | 2015 |
Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemot | 2015 |
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Ci | 2016 |
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Ci | 2013 |